<DOC>
	<DOCNO>NCT00510484</DOCNO>
	<brief_summary>This study assess effect pancrelipase delay release 24,000 unit capsule fat nitrogen absorption subject PEI due Cystic Fibrosis .</brief_summary>
	<brief_title>Study Investigating Delayed-Release Pancrelipase Patients With Exocrine Pancreatic Insufficiency Due Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Confirmed CF diagnosis two positive chloride sweat test gene analysis Confirmed PEI historical CFA &lt; 70 % without supplementation current historical fecal elastase &lt; 50Âµg/g stool ( within last 12 month ) Subjects 12 year older Currently receive treatment commercially available pancreatic enzyme product stable dose 3 month Clinically stable condition without evidence acute respiratory disease acute condition Females childbearing potential must agree continue use medically acceptable method birth control Ileus acute abdomen History fibrosing colonopathy History distal ileal obstruction syndrome within 6 month enrollment Use immunosuppressive drug Any type malignancy involve digestive tract last 5 year Known infection HIV</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Pancreatic exocrine insufficiency</keyword>
	<keyword>Cystic Fibrosis</keyword>
</DOC>